An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Itch
- Sponsors Menlo Therapeutics
- 31 Oct 2019 According to a Menlo Therapeutics media release, Over 450 patients have been enrolled in this open-label study to date.
- 06 May 2019 Planned number of patients changed from 400 to 700.
- 06 May 2019 Planned End Date changed from 1 Sep 2020 to 1 May 2021.